Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia

Arquivos Brasileiros de Cardiologia

Volumn 99, Issue 1, 2012, Pages 659-664

  Büyüklü, Mutlu ^a   Kürüm, Akif Turhan ^b   Tatlís, Ersan ^c   Set, Turan ^d  

^a ERZINCAN UNIVERSITY   (Turkey)

^b Tem Hospital   (Turkey)

^c Private Ada Medical Hospital   (Turkey)

^d ATATURK UNIVERSITY   (Turkey)

Author keywords

Anemia; Brain; Factor alpha; Heart failure drug therapy; Matrix metalloproteinase 1; Natriuretic peptide; Tumor necrosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FUROSEMIDE; INTERSTITIAL COLLAGENASE; LEVOSIMENDAN; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FUNCTIONAL STATUS; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; MALE; PROTEIN BLOOD LEVEL; SAMPLE;

AGED; ANEMIA; CARDIOTONIC AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; HEART FAILURE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PYRIDAZINES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866052068     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2012005000055     Document Type: Article

References (27)

1. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. J Clin Invest. 1992;90(2):389-98.
2. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355(9210):1126-30.
3. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106(1):55-62.
4. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5(10):1135-42.
5. Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail. 2002;4(6):681-6.
6. Figgitt DP, Gillies PS, Goa KL. Levosimendan. Drugs. 2001;61(5):613-27.
7. Kyrzopoulos S, Adamopoulos S, Parissis JT, Rassias J, Kostakis G, Iliodromitis E, et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol. 2005;99(3):409-13.
8. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol. 2004;93(10):1309-12.
9. Tziakas D, Chalikias G, Hatzinikolaou H, Stakos D, Lantzouraki A, Tentes I, et al. Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure. Cardiovasc Drugs Ther. 2005;19(6):399-402.
10. Pasqui AL, Maffei S, Di Renzo M, Pompella G, Auteri A, Puccetti L. Levosimendan improves pro/anti-inflammatory cytokines imbalance in male patients with advanced heart failure: a randomized, double-blind, placebo-controlled study. Int J Cardiol. 2011;147(2):314-5.
11. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196-202.
12. Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol. 2005;96(3):423-6.
13. Rosa EM, Osório AP, Scopel L. Levosimendan in patients with decompensated heart failure. Arq Bras Cardiol. 2008;91(2):119.
14. Ribeiro RA, Rohde LE, Polanczyk CA. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis. Arq Bras Cardiol. 2010;95(2):230-7.
15. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107(2):223-5.
16. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35(7):1737-44.
17. Buyuklu M. [Heart failure: erythropoietin in treatment of anemia]. Anadolu Kardiyol Derg. 2007;7(3):342-3.
18. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236-41.
19. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103(16):2055-9.
20. Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol. 2006;98(1):102-6.
21. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, et al. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail. 2005;7(5):882-7.
22. Jourdain P, Funck F, Bellorini M, Guillard N, Loiret J, Thebault B, et al. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail. 2003;5(2):155-60.
23. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38(7):1934-41.
24. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107(9):1278-83.
25. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;24(19):1735-43.
26. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995;27(6):1281-92.
27. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99(23):3063-70.